Ligand Pharmaceuticals
LGND
LGND
293 hedge funds and large institutions have $3.35B invested in Ligand Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 52 funds opening new positions, 114 increasing their positions, 81 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
10% more capital invested
Capital invested by funds: $3.04B → $3.35B (+$315M)
3.53% less ownership
Funds ownership: 191.07% → 187.54% (-3.5%)
42% less call options, than puts
Call options by funds: $11.2M | Put options by funds: $19.3M
Holders
293
Holding in Top 10
10
Calls
$11.2M
Puts
$19.3M
Top Buyers
| 1 | +$57.7M | |
| 2 | +$42.5M | |
| 3 | +$35.6M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$21.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.8M |
Top Sellers
| 1 | -$88.4M | |
| 2 | -$85.2M | |
| 3 | -$27.2M | |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$26.5M |
| 5 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
-$24.2M |